GLYCOLYS

Similar documents
PARTIALLY PREGELATINISED MAIZE STARCHES FOR ORAL SOLID DOSAGE FORMS

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

LYCOAT. New solutions for Film Coating from Roquette. LYCOAT for quicker quality coating

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

ORAL DOSAGE OVERVIEW

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

The unlocked synergy of DFE Pharma MCC

Critical material properties for the design of robust drug products : excipient functionality related characteristics

Formulation and Evaluation

Bonding Solutions for the. Corrugating Industry

METOLOSE: CONTENTS PAGE

YOUR ORAL SOLID DOSE. In pursuit of excipient excellence

Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets

The binding performance of DFE Pharma Starch

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

Effect of superdisintegrants and their mode of incorporation on disintegration time and release profile of carbamazepine from immediate release tablet

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)

Primellose is an excellent choice as superdisintegrant in ODT applications

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products

FLORITER. New Technology for Innovative Formulation Design.

Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig

EUDRAGIT L 100 and EUDRAGIT S 100

Short Communication. Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L. J. TIROP AND K. A. M.

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

Rationale of and Experience with the Expert System

Int. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

DEVELOPMENT OF NON SODIUM EFFERVESCENT TABLET OF PARACETAMOL USING ARGININE CARBONATE

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

ARBOCEL. Natural Raw Fibre Concentrates. Innovative Raw Fibre Concentrates for successful petfood products. J. RETTENMAIER & SÖHNE Fibres designed

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

STARCH Application Data

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients

Research Paper The Effect of Different Superdisintegrants and their Concentrations on the Dissolution of Topiramate Immediate Release Tablets

Dow Wolff Cellulosics. Using ingenuity and savvy. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

Formulation and evaluation of oro-dispersible tablets of lafutidine

Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1

Guidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples

Evaluation of different binders for roller compaction R. Wang, W. Liu, T. Durig

Easy, fast and reliable!

Easy, fast and reliable!

ZEODENT. High performing dental silicas. Engineered to Deliver Exceptional Performance and Formulating Flexibility

SCIENTIFIC DISCUSSION

Global Oilfield Solutions. Demulsifiers for the Oil Industry: Basorol

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

PRODUCT DECLARATION. Purolite C115KMR. This declaration was prepared by Purolite Corporation in February, 2017.

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

PRODUCT DECLARATION. Purolite A430MR. This declaration was prepared by Purolite Corporation in February, 2017.

Formulation and evaluation of immediate release salbutamol sulphate

Studies of Rapidly Disintegrating Tablets in the Oral Cavity Using Co-ground Mixtures of Mannitol with Crospovidone

PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS

Formulation and evaluation of fast dissolving tablet of aceclofenac

Multiple Sources of Sodium Starch Glycolate, NF: Evaluation of Functional Equivalence and Development of Standard Performance Tests

Design and development of fast Melting Tablets of Terbutaline Sulphate

Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers.

Received on: Accepted on:

(51) Int Cl.: A61K 9/20 ( ) A61K 31/41 ( )

SCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).

Formulation and Evaluation of Gastroretentive Dosage form of Ciprofloxacin Hydrochloride.

PRODUCT DECLARATION. Purolite C100MRNS. This declaration was prepared by Purolite Corporation in February, 2017.

EUDRAGIT E 100, EUDRAGIT E PO and

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

ANNEXURE -2. Excipients profiles of Compritol ATO 888, Gelucire 43/01, HPMC and PVP and have been described in the following section.

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

To study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets.

Food supplement manufacture

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION

Formulation and Evaluation of Rosuvastatin Immediate Release Tablets 10 Mg

SCIENTIFIC DISCUSSION. Efavirenz

Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch

Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good

SENTRY TM POLYOX Water Soluble Resins

Designed and manufactured specifically for pharmaceutical capsule filling

3. Drug or plant or excipients profile

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

Technical brochure StarLac

Abacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575

FlexaTrac -NTA C H E L A T I N G A G E N T

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009

Formulation and evaluation of intraorally fast dissolving tablet of olmesartan medoxomil

IJRPC 2012, 2(3) Chowdary et al ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY

B. Jayakar et. al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLET OF CELECOXIB R. Margret Chandira, Shyam Sharma, Debjit Bhowmik, B.

International Journal of Pharma and Bio Sciences NOVEL CO-PROCESSED SUPERDISINTEGRANTS IN THE DESIGN OF FAST DISSOLVING TABLETS

FORMULATION AND EVALUATION OF CEFIXIME TRIHYDRATE ORAL DISINTEGRATING AGENTS

Technical brochure CombiLac

Available Online through

The purpose of the present investigation was to design a formulation of orodispersible tablets of Etoricoxib by adopting

SCIENTIFIC DISCUSSION. Darunavir

INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND CHEMICAL SCIENCES

A New HILIC/RP Mixed-Mode Column and Its Applications in Surfactant Analysis

Karnataka Department of Pharmaceutical Technology, H.K.E. Society s College of Pharmacy, Gulbarga, Karnataka ABSTRACT KEYWORDS:

Kolliwax HCO. Technical Information. Hydrogenated castor oil powder for pharmaceutical use. = Registered trademark in many countries.

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2010/39

Design and In-vitro Evaluation of Silymarin Bilayer Tablets

Public Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.

Transcription:

ROQUETTE WORLDWIDE EUROPE FRANCE Roquette Frères Corporate Headquarters 62080 Lestrem cedex - France Telephone: + 33 3 21 63 36 00 Fax: + 33 3 21 63 38 50 FINLAND Roquette Nordica Oy PL 11 P.O.B FIN-02171 Espoo Finland Telephone: + 358-9502 4410 Fax: + 358-9-502 44111 GERMANY Roquette GmbH Schaumainkai 45 60596 Frankfurt - Deutschland Telephone: + 49 69 60 91 050 Fax: + 49 69 60 91 05 59 ITALY Roquette Italia S.p.A Via Serravalle 26 15063 Cassano Spinola Alessandria - Italia Telephone: + 39 0 143 7741 Fax: + 39 0 143 477 295 ROMANIA Roquette Romania S.A. Platforma Industrialà Sud-Vest Nr 5 Calafat Dolj - Romania Telephone: + 40 251 333 069 Fax: + 40 251 306 262 SPAIN Roquette Laisa España, S.A Avenida Jaime I, S/N. 46450 Benifaió - Valencia - España Telephone: + 34 96 178 98 00 Fax: + 34 96 178 98 10 UNITED KINGDOM Roquette UK Ltd Sallow Road Weldon Industrial Estate Corby Northants NN17 5JX United Kingdom Telephone: + 44 15 36 273000 Fax: + 44 15 36 263873 RUSSIA OOO Roquette Rus 17, Vorontsovskaya street Business Center Mosenka Capital Plaza 109147; Moscow - Russia Telephone: +7 (495) 775-75-87 Fax: +7 (495) 775-75-88 AMERICA USA Roquette America Inc. 2000 S Batavia Ave Suite 400 Geneva, IL 60134 - USA Telephone: + 1 630 463 9430 Fax: + 1 630 232 2157 MEXICO Roquette México S.A. de C.V Blvd. Bernardo Quintana 9750 of 321 Fracc. Centro sur Queretaro Qro. CP 76042 - México Telephone: + 52 44 2229 1270 Fax: + 52 44 2229 1270 ASIA CHINA Roquette Shanghai Room 501, 505, 506, K. Wah Centre No. 1010, Huai Hai Zhong Road Shanghai 200031 - China Telephone: + 86 21 54039922 Fax: + 86 21 54036606 INDIA Roquette India Private Limited Office n 702, 7th Floor Powai Plaza Hiranandani Gardens Powai Mumbai 400 076 - India Telephone: + 91 22 2570 6775 Fax: + 91 22 2570 6770 JAPAN Roquette Japan K.K. Tokyo Head Office 2F, Kasuga Business Center Building 1-15-15 Nishikata Bunkyo-Ku Tokyo 113-0024 - Japan Telephone: + 81 3 3830 1510 Fax: + 81 3 3830 1525 KOREA Roquette Korea Ltd. 17th floor Kangnam Building. 1321-1 Seocho-dong, Seocho-Ku Seoul 137 070 - Korea Telephone: + 82 2 2141 3400 Fax: + 82 2 2141 3482 SINGAPORE Roquette Singapore Pte. Ltd 438B Alexandra Road #02-09/12 Alexandra TechnoPark 119968 Singapore Telephone: + 65 6394 3350 Fax: + 65 6394 3342 www.roquettepharma.com GLYCOLYS Looking for a superdisintegrant? The unique answer for many formulations

GLYCOLYS Looking for a superdisintegrant? The unique answer for many formulations..................... ( summary Introduction.............................. page 2 GLYCOLYS general description.......... page 3 Pharmacopoeial specifications and key properties........................ page 3 An optimized production process.......... page 4 Mechanism of action...................... page 5 All modes of incorporation are possible... page 6 Regulatory............................... page 7 An extended range........................ page 7 Formulation support...................... page 8 P A G E 1

............... ( introduction ( GLYCOLYS general description The role of a superdisintegrant is to make it possible for an oral dosage form to disintegrate very quickly. This is to facilitate the rapid dissolution - and hence bio-availability - of the drug. GLYCOLYS sodium starch glycolate (SSG) is a superdisintegrant. GLYCOLYS, the market benchmark is a long established product first developed in the 1970s and wellknown - and widely used - in the pharmaceutical industry. The decades of experience gained by Roquette with its GLYCOLYS range of SSGs have made the company a supplier of choice when help is needed to develop formulations. SEM picture of GLYCOLYS GLYCOLYS sodium starch glycolate (SSG) is a white-to-off-white, odourless, tasteless, free-flowing powder. It consists of oval to spherical granules, 30µm-100µm in diameter with some less spherical granules range in size between 10µm and 35µm........ ( pharmacopoeial specifications and key properties Sodium starch glycolate has a number of different names: sodium starch glycolate (BP and USP/NF); carboxymethylamylum natricum (EP); carboxymethyl starch (USP/NF); sodium carboxymethyl starch (USP/NF). CAS Registry number: [9063-38-1]- EINECS: 232-679 - 6 The main advantage of GLYCOLYS is its versatility: Suitable for all oral dosage forms (tablets and capsules). Suitable for all manufacturing processes: - direct compression or wet granulation, - including high-shear granulation processes. Efficiency unaffected by lubricants. Different modes of incorporation are possible (intra and/or extra granularly; even mixed is possible). European Pharmacopoeia* USP / NF* Type A Type B Type C Type A Type B ph 5.5-7.5 3.0-5.0 5.5-7.5 5.5-7.5 3.0-5.0 Loss on drying 10% 10% 7% 10% 10% Sodium 2.8-4.2% 2.0-3.4% 2.8-5.0% 2.8-4.2% 2.0-3.4% Sodium chloride 7% 7% 1% 7% 7% Sodium glycolate 2% 2% 2% 2% 2% Heavy metals 20ppm 20ppm 20ppm 20ppm 20ppm Iron 20ppm 20ppm 20ppm 20ppm 20ppm *According to European Pharmacopoeia 5.4 and USP29/NF24 Second Ed. Bulk density: 0.756g/cm 3 Tapped density: 0.945g/cm 3 Specific surface area: 0.24m 2 /g Swelling capacity: in water, sodium starch glycolate swells to up to 300 times its original volume. Dynamic viscosity: < 200mPa.s for a 4% w/v aqueous dispersion. Solubility: sparingly soluble in ethanol (95%); practically insoluble in water. (Indicative values) P A G E 2 P A G E 3

............... ( an optimized production process for ideal disintegration properties ( mechanism of action Potato starch is the preferred raw material for GLYCOLYS. Its granules are relatively large (10µm - 100µm). To avoid viscosity development during disintegration process that would delay drug dissolution, cross-linking is performed on the potato starch. GLYCOLYS production process Sodium trimetaphosphate Sodium monochloroacetate NaOH Citric acid Ethanol - Water Potato starch Cross-linking Cross-linked potato starch Carboxymethylation Neutralization Washings, separation Drying Packaging GLYCOLYS sodium starch glycolate For a maximum speed of disintegration, starch ability to swell is significantly increased by rendering it more hydrophilic through carboxymethylation. For a maximum purity in the GLYCOLYS products, neutralization and washings are performed. Swelling power of different disintegrants Swelling power The mechanism of action depends on the nature of the superdisintegrant. However, swelling of the superdisintegrant particle plays a major role in all cases. The swelling power of disintegrants varies greatly from one disintegrant to another. A chain reaction involving water absorption and disruption into a solid dosage form has been proposed by Bolhuis (1982) as the mechanism of action for strongly-swelling superdisintegrants like GLYCOLYS. The mechanism explains why sodium starch glycolate is not sensitive to lubricants. Because the potato starch granule is very large, the lubricant film is unable to cover its entire surface. Water therefore reaches the starch granule at the surface of the tablet, which then swells and starts to disintegrate. Scientific studies have clearly demonstrated that lubrication has no effect on an SSG like GLYCOLYS (Bolhuis et al, 1981; Lerk et al, 1982). 100 10 1 0.1 Strongly swelling superdisintegrants Moderately swelling disintegrants Lightly swelling disintegrants Sodium starch glycolate GLYCOLYS Croscarmellose sodium Crospovidone Potato starch Microcrystalline cellulose Mechanism of action of strongly swelling superdisintegrants Water absorption of disintegrant particles at the outside of the tablet Swelling of disintegrant particles Disintegration of tablet surface structure Water penetration into the opened tablet structure Chain reaction of absorption and disruption Disintegration The mechanism also explains the superiority in hard gelatine capsules of sodium starch glycolates over other superdisintegrants. For instance, because croscarmellose s fibres retain their integrity it dissolves only partially, thus forming a viscous medium that hinders drug dissolution (Hannula et al, 1989). By contrast, GLYCOLYS sodium starch glycolate maintains granule integrity during swelling, viscosity is not altered and the drug component dissolves normally. Crospovidone is also inferior to SSG: much affected by compression forces, it loses its efficiency when a plug is formed, making it unsuitable for capsules. P A G E 4 P A G E 5

....... ( all modes of incorporation are possible: intragranularly, extragranularly or mixed GLYCOLYS can be incorporated into a formula in accordance with three commonly occurring pharmaceutical industry processes: Internal phase: the SSG can be used as a disintegrant as well as a binding enhancer for granulation. External phase: the SSG is added with other ingredients at the end of blending just before the lubricant. This is the case when formulating a direct compression blend. Mixed incorporation process (i.e. intra- and extragranular): an optimized incorporation process producing fast and efficient disintegration and dissolution, while improving the general characteristics of the dosage form (hardness, friability ). Effect of GLYCOLYS mode of incorporation on tablet disintegration time 2500 In trials carried out with mannitol PEARLITOL -based tablets containing 5% GLYCOLYS, tablet disintegration time was dramatically reduced, irrespective of the mode of incorporation. Hardness and friability were similar to the control tablets. It will be noted that the best results obtained with GLYCOLYS occur when the superdisintegrant is used extragranularly. When the SSG is totally incorporated intragranularly, the disintegration kinetic is reduced due to the slow disruption mechanism in the tablet surface structure. A mixed process also reduces GLYCOLYS efficiency. However, in all cases the addition of GLYCOLYS reduces disintegration times relative to the control. In specific cases using wet granulation, GLYCOLYS LV (low viscosity grade) is more appropriate, resulting in even shorter disintegration times (see separate GLYCOLYS LV document). GLYCOLYS LV For wet granulation and high shear processes GLYCOLYS Low ph........................................ ( regulatory Roquette s entire GLYCOLYS SSG range complies with EP and USP/NF Pharmacopoeias. ( an extended range GLYCOLYS For ph-sensitive drugs Multipurpose For all other requirements Disintegration time (s) 2000 1500 1000 500 0 Control Intragranularly Extragranularly 50 intra/50 extra P A G E 6 P A G E 7

........ ( formulation support Roquette has very wide experience of GLYCOLYS sodium starch glycolate, not least in oral solid dosage form formulations. We are dedicated to providing you with the technical support and help you may need to develop your own formulations. Download examples of formulations at: www.roquettepharma.com Alternatively, fill in our Formulation Assistance Request and we will help you choose the excipients that will give you the keys you need for your formulation trials. Through still closer collaboration with you we can also arrive at a comprehensive formulation for your product; we can also provide you with placebos or prototypes. Literature Bolhuis et al, 1982, Acta Pharm. Technologica 28(2), 111-114 Bolhuis et al, 1981, Journal of Pharm. Sciences 70(12), 1328-1330 Lerk et al, 1982, Pharm. Acta Helv. 57, 282-286 Hannula et al, 1989, Acta Pharm. Fennica 98, 189-196 The information contained in this document is to the best of our knowledge true and accurate but all instructions, recommendations or suggestions are made without any guarantee. Since the conditions of use are beyond our control, we disclaim any liability for loss and/or damage suffered from use of these data or suggestions. Furthermore, no liability is accepted if use of any product in accordance with these data or suggestions infringes any patent. No part of this document may be reproduced by any process without our prior written permission. Registered trademarks of Roquette Frères Roquette Frères S.A. - 03/2010 P A G E 8

GLYCOLYS at a glance Suitable for tablets and capsules Low incorporation level: 2-5% in tablets 4-8% in capsules Usable in internal and external phases, or mixed Not sensitive to lubricant Not influenced by compression force Low hygroscopicity Chemically stable In use as superdisintegrant for more than 30 years Can be sourced reliably worldwide